/zigman2/quotes/201150432/composite TMO -1.32%
May 27, 2020 (Market Insight Reports) -- The Cell Line Development Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2026. The Cell Line Development market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries. This Cell Line Development Market study provides comprehensive data that enhances the understanding, scope, and application of this report.
The global cell line development market size was estimated at USD 2.67 billion in 2015 and is anticipated to grow at a CAGR of 12.9% over the forecast period
The Prominent Key Players of Cell Line Development Market - Thermo Fisher Scientific /zigman2/quotes/201150432/composite TMO -1.32% , Sartorius AG, Promega Corporation, and Merck KGaA
Get Sample PDF Copy of Latest Research on Cell Line Development Market 2020
The global cancer burden is increasing, and thus, cancer therapies must be modified according to regional and national priorities. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, of which 9.5 million cases were in men and 8.5 million in women. Lung and breast cancers are the most common prevalent cancers, which contributed to about 12.3% of the total number of new cases that were diagnosed in 2018. Colorectal cancer was the third-most common cancer, with a prevalence of 1.8 million new cases in 2018, according to the World Cancer Research Fund.
Key Market Trends
Mammalian Cell Line Development is Expected to Register Rapid Growth Over the Forecast Period
It has been observed that since the year 2006, there has been a rise in the number of recombinant protein therapeutics approved by the FDA. National Institute of Health has stated that there were more than 15 novels recombinant protein therapeutics approved by the US Food and Drug Administration (FDA) each year. In addition, the expiration of the branded drugs has given rise to the emergence of biosimilars.
The United States Dominates the Market
The United States has a better healthcare infrastructure, compared to most of the developed countries. The presence of key players in the United States is the major factor propelling the growth of the market studied in the country. Furthermore, support from the US government to accelerate the research in the biotechnology and biopharmaceutical industry is augmenting the demand for cell line development.
Asia Pacific is expected to witness the highest CAGR over the forecast period due to the growing development in Asian countries such as India, China, and Japan. Also, the Asia Pacific market is posing a great opportunity for new entrants to establish their market in this region.
Regions Are covered By Cell Line Development Market Report 2020 To 2026.North America, Europe, China, Japan, Southeast Asia, India, North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia).
Explore Full Report With Detailed TOC Here:
Significant Key Factor Analysis of the Cell Line Development Market:
Business overview- An exhaustive description of the company's operations and business divisions